Implementation and Evaluation of an Electronic Alert to Encourage Targeted Screening for HIV Infection at Foch Hospital According to Socio-demographic Criteria

NCT ID: NCT03991767

Last Updated: 2020-01-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

297 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-04

Study Completion Date

2019-10-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In 2013 in France, 29,000 people are reported to be unaware of their HIV status. HIV testing is a priority in France where one third of all diagnoses remain late despite 5 million annual tests. It is recommended to offer at least one HIV test to the general population, over the life course, when seeking care and more frequently to populations at risk. Several international and national articles have shown that emergency screening is feasible and well accepted. But also that during systematic screening few infections were discovered, and the majority of newly diagnosed people belonged to the most exposed groups.

Our hypothesis is that an electronic alert would identify people who are unaware of their HIV status. This alert would be based on two data: social data (French health coverage) and the country of birth. This alert is only relevant in high-prevalence regions, as is the case in the Ile de France region.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Testing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

period 1

Period 1: Retrospective period:

Collection of data from the 12 months preceding the start of the research of hospitalized patients:

* number of hospitalizations,
* number of HIV serologies performed,
* number of patients with socio-demographic criteria justifying HIV screening.

Start of research: Implementation of the "POP-UP" electronic alert

Period 2: Prospective period: 18 months POP-UP opens for patient who meet the eligibility criteria.

Six possibility to answer:

1. Patient accept to participate: patient is include and receive HIV serology during their hospitalization.
2. Not time to answer to the alert
3. Patient already has a serology less than 3 months old
4. Patient followed for a known HIV infection.
5. Patient who refused the test
6. Clinical condition of the patient not allowing his no opposition Only choice 1 include patient The response close the electronic alert, but it re-opens when the medical file is re-consulted (2/ and 6/) or new hospitalization.

Group Type EXPERIMENTAL

"POP-UP" electronic alert

Intervention Type OTHER

Implementation of the "POP-UP" electronic alert for all patients with eligibility criteria

Serology HIV

Intervention Type DIAGNOSTIC_TEST

Realization of HIV serology for included patients.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

"POP-UP" electronic alert

Implementation of the "POP-UP" electronic alert for all patients with eligibility criteria

Intervention Type OTHER

Serology HIV

Realization of HIV serology for included patients.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient hospitalized at Foch Hospital over 18 years of age.
* Patient with AME or CMU and/or CMUc, or patient born in one of the following countries/regions: Sub-Saharan Africa, Haiti, South America, Asia, Eastern Europe, Guadeloupe, Martinique and Guyana

Exclusion Criteria

* Patient whose vital prognosis at the time of admission does not allow him/her to indicate his/her non-opposition to an HIV test.
* Patient being followed for a known HIV infection.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hopital Foch

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Zucman, MD

Role: STUDY_DIRECTOR

FOCH Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hopital Foch

Suresnes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016/51

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sexual Risks in Prep Users
NCT03975517 COMPLETED